Johnson & Johnson JNJ

$282.55 -3.20 (-1.12%)

Valuation

Market cap
687,888,896,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.62
P/E (forward)
25.50
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,104,300
Avg volume
7,314,380
Day's range
$282.33 – $290.25
Shares out
2,407,310,000
Stochastic %K
69%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

openclassaction2 Nov 17, 1:58 AM
$JNJ 68,029 talc cases were pending in the jnj mdl as of june 1, no nationwide settlement, per open class actions. lawsuit stage, nothing to claim. the docket is the overhang
0 replies
haha1978 Nov 16, 11:26 PM
$SLS $JNJ Hope you bought SLS JNJ!!!!
0 replies
AnalystNick121 Nov 16, 8:54 PM
$JNJ 🧴 JNJ: Johnson & Johnson combines pharmaceutical innovation, medical devices, and global healthcare demand. 📈 Key Catalysts: 💊 New drug launches 🏥 Medical-device growth 🧪 Pharmaceutical innovation 🌍 Global healthcare demand Its diversified healthcare platform supports long-term business stability and growth.
0 replies
UncleSteven Nov 16, 8:52 PM
$JNJ See what I mean? Leaving $NVDA at $152 for defensive stocks like this when the demand for AI has only grown. Ridiculous PE ratios. Earnings tomorrow! See you there.
0 replies
SellasgpsCurativeBAT11 Nov 16, 6:13 PM
$ABBV $BMY $JNJ $PFE $SLS Part 2. "....Michael Anglestein, a senior respiratory biologics sales specialist at AstraZeneca, then turned the conversation to Sellas' galinpepimut-S (GPS). "The REGAL Phase 3 trial for AML is a game changer for CR1 & CR2 patients," Anglestein said. "The trial has been going on for 5 1/2 years with no futility and very few side effects." ..." that GPS and Sellas' other clinical candidate, SLS009, would be "game changers" for AML and potentially other cancers..." Rob Tomko, a medical-device industry executive, agreed. "Going to be an absolute blockbuster once the results come out," Tomko said. "I couldn't agree moreịẠại A Stocktwits user also highlighted a LinkedIn comment attributed to Michael Frascello, a product director at Johnson & Johnson, that appears to have since been deleted. "Agree Sellas GPS and REGAL will be a game changer for AML care," Frascello reportedly said...' ✌️🙏❤️‍🩹
1 replies
CasperPuff Nov 16, 6:05 PM
$JNJ chart looking good
0 replies
SellasgpsCurativeBAT11 Nov 16, 6:00 PM
$SLS $JNJ $PFE $ABBV $BMY Sellas BOD has been working on a BO for almost a year now. I expect an Immediate BO of Sellas after GPS Regal Pivotal Registrational Phase 3 Study Transformative Data. My # 1 Pick is $JNJ Executives have been openly touting Sellas GPS Breakthrough. 2. ABBV Ventoclax will become Obsolete after GPS FDA approval. 3. BMY Onureg will become Obselete after GPS FDA approval. 4. Pfizer CEO Bourla close ties to Sellas CEO Dr. Stergiou and planned focus on Oncology. ✌️🙏❤️‍🩹
1 replies
notreload_ai Nov 16, 5:21 PM
$JNJ agreed to acquire Ollin Biosciences for $2.2B upfront to add OLN324, a Phase 3 bispecific antibody for wet AMD and DME. https://notreload.xyz/xy/jnj-acquires-ollin-biosciences-for-phase-3-eye-drug/
0 replies